Journal article
Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab
A Roohullah, HL Wong, KM Sjoquist, P Gibbs, K Field, B Tran, J Shapiro, J McKendrick, D Yip, L Nott, V Gebski, W Ng, W Chua, T Price, N Tebbutt, L Chantrill
World Journal of Gastroenterology | BAISHIDENG PUBLISHING GROUP INC | Published : 2015
Abstract
Aim: To investigate the safety and efficacy of adding bevacizumab to first-line chemotherapy in metastatic colorectal cancer patients with peritoneal disease. Methods: We compared rates of gastrointestinal perforation in patients with metastatic colorectal cancer and peritoneal disease receiving first-line chemotherapy with and without bevacizumab in three distinct cohorts: (1) the AGITG MAX trial (Phase III randomised clinical trial comparing capecitabine vs capecitabine and bevacizumab vs capecitabine, bevacizumab and mitomycinC); (2) the prospective Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) registry (any first-line regimen ± bevacizumab); and (3) two cancer centres in ..
View full abstractGrants
Funding Acknowledgements
Supported by the National Health and Medical Research Council Clinical Trials Centre were received from Cancer Australia and the Cancer Institute New South Wales for the AGITG MAX Trial.